The Overture Study is a randomized, controlled, single-blind multi-center clinical trial using the GammaSense Stimulation system to study safety, tolerability, and efficacy in people with mild to moderate cognitive impairment.
The Overture Study (CA-0005) is a Phase I/II randomized, controlled, single-blind multi-center clinical trial using the GammaSense Stimulation device to study safety, adherence rates and efficacy in subjects with mild to moderate cognitive impairment (MMSE 14-26) who are age 55 and older. Subjects who pass screening will be randomized (ratio 2:1 Treatment to Control). Subjects and their caregivers will be blinded to their randomization group, as will key raters at each site. The device will be used for 60 minutes daily during the 6-month therapy phase, followed by a one month safety follow-up visit.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
60
Proprietary auditory and visual sensory stimulation device.
Proprietary auditory and visual sensory stimulation device.
Brain Matters Research
Delray Beach, Florida, United States
Brain Matters Research
Stuart, Florida, United States
ActivMed Practices & Research, Inc
Methuen, Massachusetts, United States
Boston Center for Memory
Newton, Massachusetts, United States
The Cognitive and Research Center of New Jersey
Springfield, New Jersey, United States
Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)
A widely accepted, validated measure of cognitive function in Alzheimer's Disease consisting of 14 questions that result in a score ranging from 0 to 90 with higher scores representing greater cognitive impairment
Time frame: Quarterly over 6 months
Amyloid PET/CT
Time frame: Quarterly over 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.